Everest Medicines (HKG:1952) said the first patient was dosed in a clinical trial of its mRNA cancer vaccine EVM16 at Peking University Cancer Hospital,
The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in advanced or recurrent solid tumors.
The clinical trial of EVM16 is being conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, according to a Thursday news release.
Shares of the biopharmaceutical company soared 18% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。